New Phase II data for Novartis AG’s iptacopan has reinforced its potential in the rare disease C3 glomerulopathy (C3G) less than a year after ChemoCentryx, Inc. and Vifor Pharma Group’s competitor Tavneos (avacopan) disappointed with its topline Phase II data. The Swiss firm is now forging ahead with the Phase III APPEAR-C3G study for the product in C3G.
Novartis’s Iptacopan Pulls Ahead In Race To Fill Nephrology Unmet Need
Phase II Trial In Rare Kidney Disease Is A Success
The first-in-class candidate met two primary endpoints in a Phase II trial for C3 glomerulopathy, suggesting potential edge over ChemoCentryx and Vifor’s competitor avacopan.
More from Genitourinary
• By
Purespring has just raised $105m from an investor syndicate who are betting it can develop the first gene therapy for kidney disease and learn from setbacks experienced in the space.
• By
Gazyva could add the autoimmune condition to its label following a Phase III hit, but it might struggle to differentiate itself from Benlysta and Lupkynis.
• By
Following the pivotal data on Alnylam’s Amvuttra, all eyes turn to the next amyloidosis readout – that of AstraZeneca and Ionis’ Wainua. And the UK major’s ambitions do not stop there.
• By
The big pharma’s second selection in the alliance shows novel cardiovascular therapies are high on its priority list
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.